Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BioNTech
Biotech
BioNTech pays $800M to take control of potential Keytruda killer
BioNTech is paying $800 million upfront to buy Biotheus and secure full rights to a leading prospect in the white-hot PD-L1xVEGF-A bispecific space.
Nick Paul Taylor
Nov 13, 2024 6:45am
FDA puts partial hold on BioNTech-OncoC4 phase 3 trial
Oct 18, 2024 12:55pm
2 cancer biotechs merge, creating global footprint
Sep 25, 2024 10:54am
FDA allows BioNTech-MediLink ADC trial to resume at lower doses
Aug 19, 2024 8:45am
Pfizer, BioNTech combo mRNA shot latest to lose to flu strain B
Aug 16, 2024 8:25am
BioNTech ends work on Genmab-partnered bispecific antibody
Aug 5, 2024 7:50am
